Boston Scientific (BSX) Projected to Post Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSX) is projected to announce its Q3 2025 results before the market opens on Wednesday, October 22nd. Analysts expect the company to announce earnings of $0.71 per share and revenue of $4.9663 billion for the quarter. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 22, 2025 at 8:00 AM ET.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 EPS. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Stock Up 1.3%

BSX opened at $100.56 on Tuesday. Boston Scientific has a one year low of $80.64 and a one year high of $109.50. The company has a fifty day moving average price of $101.25 and a 200-day moving average price of $101.85. The firm has a market capitalization of $149.01 billion, a P/E ratio of 59.86, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Several large investors have recently modified their holdings of BSX. Man Group plc grew its stake in shares of Boston Scientific by 157.9% in the second quarter. Man Group plc now owns 2,137,443 shares of the medical equipment provider’s stock worth $229,583,000 after purchasing an additional 1,308,711 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Boston Scientific by 59.5% in the second quarter. AQR Capital Management LLC now owns 1,843,193 shares of the medical equipment provider’s stock worth $197,111,000 after buying an additional 687,364 shares during the period. Viking Global Investors LP lifted its holdings in Boston Scientific by 28.1% in the second quarter. Viking Global Investors LP now owns 3,045,764 shares of the medical equipment provider’s stock worth $327,146,000 after buying an additional 669,000 shares during the period. Sofinnova Investments Inc. purchased a new stake in Boston Scientific in the second quarter worth about $46,315,000. Finally, Meridiem Capital Partners LP lifted its holdings in Boston Scientific by 227.5% in the second quarter. Meridiem Capital Partners LP now owns 426,319 shares of the medical equipment provider’s stock worth $45,791,000 after buying an additional 296,129 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. UBS Group upped their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday. BTIG Research upped their target price on shares of Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Raymond James Financial lifted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Finally, Truist Financial lifted their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.